No results for ‘’
Ind-Swift Laboratories Ltd
₹187.38
(11.09%)
Thu, 25 Jun 2026, 08:36 am
Health Technology
Pharmaceuticals: Major
24.5KInd-Swift Laboratories PB Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 7.17 | 6.87 | 3.31 | 1.53 | 3.32 | 3.45 | 3.80 | 0 | 0 | 0 | 0 | 0 | 11.75 | 6.58 | 0 | 0 | 0 | 6.86 | 1.08 | 2.39 |
| Price to book ratio | 1.34 | 0.41 | 0.32 | 0.16 | 0.42 | 0.57 | 0.42 | 0.21 | 0.22 | 0.22 | 0.36 | 0.28 | 0.47 | 0.31 | 0.20 | 0.70 | 0.65 | 0.48 | 0.72 | 0.49 |
| Price to sales ratio | 0.76 | 0.36 | 0.23 | 0.11 | 0.24 | 0.30 | 0.24 | 0.16 | 0.17 | 0.20 | 0.29 | 0.20 | 0.34 | 0.28 | 0.14 | 0.48 | 0.38 | 0.27 | 0.34 | 1.06 |
| Price to cash flow ratio | 20.38 | 4.05 | 2.32 | 0.89 | 9.57 | 0 | 0 | 0 | 5.73 | 4.80 | 4.81 | 1.51 | 1.77 | 2.35 | 1.78 | 7.97 | 8.30 | 4.66 | 0 | 0 |
| Enterprise value | 454Cr | 405Cr | 405Cr | 419Cr | 721Cr | 1074Cr | 1302Cr | 1371Cr | 1474Cr | 1530Cr | 1622Cr | 1367Cr | 1332Cr | 1267Cr | 1064Cr | 1399Cr | 1314Cr | 1161Cr | 294Cr | 166Cr |
| Enterprise value to EBITDA ratio | 7.31 | 6.03 | 4.96 | 3.59 | 5.62 | 6.26 | 7.31 | 19.14 | 24.96 | 17.22 | 15.12 | 12.89 | 9.91 | 10.05 | 7.36 | 7.58 | 6.27 | 5.03 | 0.96 | 0 |
| Debt to equity ratio | 1.15 | 0.94 | 0.94 | 1.04 | 1.31 | 1.42 | 1.23 | 1.43 | 1.85 | 2.37 | 2.79 | 2.32 | 1.95 | 1.82 | 1.49 | 1.61 | 1.56 | 1.24 | 0.25 | 0.03 |
| Return on equity % | 0 | 7.24 | 9.74 | 11.60 | 13.90 | 17.43 | 12.70 | -14.12 | -15.60 | -18.12 | -10.44 | -7.41 | 4.03 | 5.02 | -3.37 | -0.50 | -0.35 | 7.38 | 71.92 | 23.75 |
Ind-Swift Laboratories Ltd Price to Book Ratio
The Ind-Swift Laboratories Ltd Price to Book Ratio is a key financial metric used by investors to evaluate Ind-Swift Laboratories Ltd's valuation, profitability, and overall financial performance. Tracking the Ind-Swift Laboratories Ltd Price to Book Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Ind-Swift Laboratories Ltd (NSE: INDSWFTLAB, BSE: 532305) is currently trading at ₹187.38, with a market capitalization of ₹1626.01Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Ind-Swift Laboratories Ltd Price to Book Ratio is essential for fundamental analysis.
Ind-Swift Laboratories Ltd Price to Book Ratio Current Value
The current Ind-Swift Laboratories Ltd Price to Book Ratio stands at 0.49.
The Ind-Swift Laboratories Ltd Price to Book Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Ind-Swift Laboratories Ltd Price to Book Ratio Historical Trend
The Ind-Swift Laboratories Ltd Price to Book Ratio has shown the following historical trend:
- 2024: 0.49
- 2023: 0.72
- 2022: 0.48
- 2021: 0.65
- 2020: 0.70
The decline in Ind-Swift Laboratories Ltd Price to Book Ratio indicates improving financial efficiency or better earnings growth.
What Ind-Swift Laboratories Ltd Price to Book Ratio Indicates for Investors
The Ind-Swift Laboratories Ltd Price to Book Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/B ratio shows how the market values company assets relative to book value.
Ind-Swift Laboratories Ltd Price to Book Ratio Analysis Summary
The Ind-Swift Laboratories Ltd Price to Book Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Ind-Swift Laboratories Ltd Price to Book Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Ind-Swift Laboratories Ltd Price to Book Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.